News stories about Oramed Pharmaceuticals (NASDAQ:ORMP) have trended somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Oramed Pharmaceuticals earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 44.9444209851961 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Heavy … – First News 24 (firstnewspaper24.com)
- Consensus Buy Analysis: Oramed Pharmaceuticals Inc. (ORMP) – Street Observer (press release) (streetobserver.com)
- Contrasting Oramed Pharmaceuticals (ORMP) & OvaScience (OVAS) (americanbankingnews.com)
- Oramed Pharmaceuticals Inc. (ORMP) Expected to Post Quarterly Sales of $610,000.00 (americanbankingnews.com)
ORMP has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Oramed Pharmaceuticals in a report on Thursday, October 5th. ValuEngine upgraded shares of Oramed Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th.
In other news, Director Xiaopeng Li purchased 89,636 shares of Oramed Pharmaceuticals stock in a transaction dated Wednesday, August 2nd. The stock was acquired at an average cost of $8.50 per share, for a total transaction of $761,906.00. Following the acquisition, the director now directly owns 206,350 shares in the company, valued at $1,753,975. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 27.50% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: “Oramed Pharmaceuticals (ORMP) Given News Impact Score of 0.18” was first published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.truebluetribune.com/2017/10/13/oramed-pharmaceuticals-ormp-given-news-impact-score-of-0-18.html.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.
Receive News & Ratings for Oramed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.